

1 Supplementary Materials for
2 **Monoclonal antibodies targeting surface exposed epitopes of *Candida albicans***
3 **cell wall proteins confer *in vivo* protection in an infection model**

4 Palliyil et al

5 Corresponding authors: Soumya Palliyil, soumya.palliyil@abdn.ac.uk, Carol A Munro,

6 c.a.munro@abdn.ac.uk


7

8 LIST OF SUPPLEMENTARY MATERIALS

9 Figure S1


10 Table S1

11 A




12

13 B




14

15 C



16



17 D

18

19 **Fig. S1. Engulfment of anti-Candida mAb treated C. albicans cells by mouse macrophages.**

20 *The time taken for J774.1 macrophages to ingest live Candida cells following initial cell-cell*

21 *contact verses the percentage of uptake events are plotted. (A) wt (B) Pga31 mAb (C) Utr2 mAb*

22 *(D) positive control murine mAb. The rate of engulfment of all antibody-treated cells was faster*

23 *than that of untreated C. albicans. Bars represent the percentages of uptake events (n = 6 videos*

24 *for each antibody group from two biological replicates).*

25

26

Treatment group	Mean (\pm SD) change in body weight
Isotype Control	-13.77 \pm 3.00
Pga31 mAb	-9.49 \pm 2.56
Utr2 mAb	-10.79 \pm 1.80
Saline only	-11.59 \pm 2.89

27

28 **Table S1. Average weight change in mice in study 1** Groups of mice (n=6) were treated with
29 either Pga31 mAb (15 mg/kg), Utr2 mAb (15 mg/kg), mouse IgG2a isotype control (15 mg/kg) or
30 saline, 3 h pre and 24 h post-infection in a murine model of disseminated candidiasis. Data
31 represents mean change in body weight \pm SD (g) at day 2 compared with day 0 in mouse study 1.

32

33

34

35

36